Earnings Feed
Start Free
Home/Insiders/NABEL ELIZABETH G
NE
SEC Insider//CIK 0001619929

NABEL ELIZABETH G

CIK 00016199299 companiesSOUTH SAN FRANCISCO, CA
SEC Profile

Transactions

50

Companies

9

Filings

11

CIK

0001619929

Recent Transactions

50 trades
  • Award
    Lyell Immunopharma, Inc.$LYEL

    Option (right to buy)

    2026-06-10+9,250→ 9,250 total
  • Award
    Moderna, Inc.$MRNA

    Restricted Stock Units

    2026-05-06+8,371→ 8,371 total
  • Exercise/Conversion
    Moderna, Inc.$MRNA

    Restricted Stock Units

    2026-04-30−16,233→ 0 total
  • Exercise/Conversion
    Moderna, Inc.$MRNA

    Common Stock

    2026-04-30+16,233→ 19,317 total
  • Tax Payment
    Medtronic plc$MDT

    Ordinary Shares

    2026-04-28$81.90/sh−207→ 19,584 total
  • Award
    Medtronic plc$MDT

    Ordinary Shares

    2026-04-27+2,111→ 19,791 total
  • Award
    Lyell Immunopharma, Inc.$LYEL

    Option (right to buy)

    2025-05-15+130,000→ 130,000 total
  • Exercise/Conversion
    Moderna, Inc.$MRNA

    Common Stock

    2025-04-30+979→ 3,084 total
  • Award
    Moderna, Inc.$MRNA

    Restricted Stock Units

    2025-04-30+16,233→ 16,233 total
  • Exercise/Conversion
    Moderna, Inc.$MRNA

    Restricted Stock Units

    2025-04-30−979→ 0 total
  • Tax Payment
    Medtronic plc$MDT

    Ordinary Shares

    2025-04-29$84.60/sh−216→ 17,615 total
  • Award
    Medtronic plc$MDT

    Ordinary Shares

    2025-04-28$84.04/sh+2,083→ 17,831 total
  • Disposition to Issuer
    Accolade, Inc.

    Restricted Stock Units

    2025-04-08−35,021→ 0 total
  • Disposition to Issuer
    Accolade, Inc.

    Restricted Stock Units

    2025-04-08−12,489→ 0 total
  • Disposition to Issuer
    Accolade, Inc.

    Common Stock

    2025-04-08$7.03/sh−41,982→ 0 total
  • Award
    Accolade, Inc.

    Restricted Stock Units

    2025-03-03+12,489→ 12,489 total
  • Exercise/Conversion
    Accolade, Inc.

    Restricted Stock Units

    2025-02-28−2,178→ 0 total
  • Exercise/Conversion
    Accolade, Inc.

    Common Stock

    2025-02-28+2,178→ 41,982 total
  • Exercise/Conversion
    Accolade, Inc.

    Restricted Stock Units

    2024-12-02−2,179→ 2,178 total
  • Exercise/Conversion
    Accolade, Inc.

    Common Stock

    2024-12-02+2,179→ 39,804 total
  • Exercise/Conversion
    Accolade, Inc.

    Restricted Stock Units

    2024-09-03−2,179→ 4,357 total
  • Exercise/Conversion
    Accolade, Inc.

    Common Stock

    2024-09-03+2,179→ 37,625 total
  • Exercise/Conversion
    Accolade, Inc.

    Restricted Stock Units

    2024-08-06−9,196→ 0 total
  • Award
    Accolade, Inc.

    Restricted Stock Units

    2024-08-06+35,021→ 35,021 total
  • Exercise/Conversion
    Accolade, Inc.

    Common Stock

    2024-08-06+9,196→ 35,446 total
  • Award
    Lyell Immunopharma, Inc.$LYEL

    Option (right to buy)

    2024-06-14+130,000→ 130,000 total
  • Exercise/Conversion
    Accolade, Inc.

    Common Stock

    2024-05-31+2,179→ 26,250 total
  • Exercise/Conversion
    Accolade, Inc.

    Restricted Stock Units

    2024-05-31−2,179→ 6,536 total
  • Award
    Moderna, Inc.$MRNA

    Restricted Stock Units

    2024-05-06+979→ 979 total
  • Award
    Moderna, Inc.$MRNA

    Stock Option (Right to Buy)

    2024-05-06+5,668→ 5,668 total
  • Exercise/Conversion
    Moderna, Inc.$MRNA

    Restricted Stock Units

    2024-05-03−732→ 0 total
  • Exercise/Conversion
    Moderna, Inc.$MRNA

    Common Stock

    2024-05-03+732→ 2,105 total
  • Tax Payment
    Medtronic plc$MDT

    Ordinary Shares

    2024-05-01$80.89/sh−192→ 15,674 total
  • Award
    Medtronic plc$MDT

    Ordinary Shares

    2024-04-29$80.86/sh+2,165→ 15,866 total
  • Award
    Accolade, Inc.

    Restricted Stock Units

    2024-03-01+8,715→ 8,715 total
  • Exercise/Conversion
    Accolade, Inc.

    Restricted Stock Units

    2024-02-29−1,751→ 0 total
  • Exercise/Conversion
    Accolade, Inc.

    Common Stock

    2024-02-29+1,751→ 24,071 total
  • Exercise/Conversion
    Accolade, Inc.

    Common Stock

    2023-11-30+1,751→ 22,320 total
  • Exercise/Conversion
    Accolade, Inc.

    Restricted Stock Units

    2023-11-30−1,751→ 1,751 total
  • Award
    Lyell Immunopharma, Inc.$LYEL

    Option (right to buy)

    2023-09-08+55,000→ 55,000 total
  • Exercise/Conversion
    Accolade, Inc.

    Common Stock

    2023-08-31+1,752→ 20,569 total
  • Exercise/Conversion
    Accolade, Inc.

    Restricted Stock Units

    2023-08-31−1,752→ 3,502 total
  • Award
    Accolade, Inc.

    Restricted Stock Units

    2023-08-18+9,196→ 9,196 total
  • Exercise/Conversion
    Accolade, Inc.

    Common Stock

    2023-07-25+14,060→ 18,817 total
  • Exercise/Conversion
    Accolade, Inc.

    Restricted Stock Units

    2023-07-25−14,060→ 0 total
  • Award
    Lyell Immunopharma, Inc.$LYEL

    Option (right to buy)

    2023-06-16+65,000→ 65,000 total
  • Exercise/Conversion
    Accolade, Inc.

    Restricted Stock Units

    2023-05-31−1,752→ 5,254 total
  • Exercise/Conversion
    Accolade, Inc.

    Common Stock

    2023-05-31+1,752→ 4,757 total
  • Award
    Moderna, Inc.$MRNA

    Restricted Stock Units

    2023-05-03+732→ 732 total
  • Award
    Moderna, Inc.$MRNA

    Stock Option (Right to Buy)

    2023-05-03+4,601→ 4,601 total

Companies

9

Recent Filings

11

Address

C/O LYELL IMMUNOPHARMA, INC. 201 HASKINS WAY, SUITE 101

SOUTH SAN FRANCISCO, CA, 94080

View on SEC.gov